Clinical Trial Update: Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating prednisolone with or without the anti-CD20 antibody rituximab for autoimmune hemolytic anemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia

Drugs mentioned

• Prednisolone (Prednisolone)
• Rituximab (rituximab)

Snippet

Sponsor: Copenhagen University Hospital at Herlev | Conditions: Anemia, Hemolytic, Autoimmune | Phase 3 | Status: COMPLETED